Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4, R.sup.5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (M.sup.pro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

Disclosed are compounds of formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII-selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

Disclosed are compounds of formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII-selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

Disclosed is a compound containing a specific structure having an azomethine part, the compound being reversibly fluidized and non-fluidized by being irradiated with light.

Disclosed is a compound containing a specific structure having an azomethine part, the compound being reversibly fluidized and non-fluidized by being irradiated with light.

The objective of the present invention is to provide a method of producing each high purity imidazole dipeptide in large quantities on an industrial scale, regardless of the type of animal extract employed. The objective is achieved by a method of producing a purified imidazole dipeptide composition, including the step (1) of subjecting an animal extract treatment solution containing at least two types of imidazole dipeptides to adsorption treatment carried out by bringing the solution into contact with a hydrophobic adsorption resin to adsorb the imidazole dipeptides onto the hydrophobic adsorption resin; and the step (2) of subjecting the hydrophobic adsorption resin adsorbing the imidazole dipeptides to elution treatment using an aqueous solution to mutually separate and collect the imidazole dipeptides to purify an imidazole dipeptide.

The objective of the present invention is to provide a method of producing each high purity imidazole dipeptide in large quantities on an industrial scale, regardless of the type of animal extract employed. The objective is achieved by a method of producing a purified imidazole dipeptide composition, including the step (1) of subjecting an animal extract treatment solution containing at least two types of imidazole dipeptides to adsorption treatment carried out by bringing the solution into contact with a hydrophobic adsorption resin to adsorb the imidazole dipeptides onto the hydrophobic adsorption resin; and the step (2) of subjecting the hydrophobic adsorption resin adsorbing the imidazole dipeptides to elution treatment using an aqueous solution to mutually separate and collect the imidazole dipeptides to purify an imidazole dipeptide.

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containg such compounds.

Provided are compounds of Formula (I):

##STR00001##

and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).